March 14th 2024
Results from the phase 3 RATIONALE 302 trial led to the approval of tislelizumab for patients with unresectable or metastatic esophageal squamous cell carcinoma.
January 24th 2024
Equalizing Inequities™ in Multiple Myeloma Care: Shining a Light on Current Barriers and Opportunities for Improved Outcomes
View More
Medical Crossfire®: Critical Questions on Diagnosis, Sequencing, and Selection of Systemic and Radioligand Therapy Options for Patients with GEP-NETs
View More
Community Practice Connections™: 8th Annual School of Gastrointestinal Oncology®
View More
2024 Miami International Symposium of Gastrointestinal Oncology (ISGIO)
October 11-12, 2024
Register Now!
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
The Next Wave in Biliary Tract Cancers: Leveraging Immunogenicity to Optimize Patient Outcomes in an Evolving Treatment Landscape
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Pembrolizumab Active in Heavily Pretreated Esophageal Tumors
November 29th 2017Treatment with the anti–PD-1 antibody pembrolizumab resulted in durable antitumor activity with manageable side effects in patients with heavily pretreated, PD-L1–positive advanced esophageal carcinoma, according to phase IB results of the KEYNOTE-028 study.
Adjuvant Chemo Improved Survival in Gastroesophageal Cancer
October 2nd 2017Treatment with adjuvant chemotherapy improved the overall survival of locally advanced gastroesophageal adenocarcinoma in patients treated with preoperative chemoradiotherapy and resection, according to the results of an analysis of the National Cancer Database.
PET Scans Helped Tailor Induction Chemotherapy for Esophageal Cancers
January 17th 2017Using PET scans during induction chemotherapy for esophageal cancer, researchers were able to assess patient response to treatment and adjust their therapy, leading to an improved rate of pathologic complete response prior to surgery.
Long-Term Results Confirm Superior Outcomes of Neoadjuvant Chemoradiotherapy for Esophageal Cancer
August 7th 2015Long-term results of the CROSS study have confirmed that neoadjuvant chemoradiotherapy added to surgery should be the standard of care in esophageal or esophagogastric junction carcinoma.
Esophagogastric Junction and Gastric Adenocarcinoma: Current Challenges and Future Directions
June 15th 2014Both esophageal cancer and stomach cancer are aggressive malignancies with contrasting risk factors, histologies, and molecular characteristics-yet for the most part comparable therapeutic approaches.
Multimodality Therapy for Esophageal Cancer
November 15th 2010Recent developments in the epidemiology, staging, and treatment of esophageal and gastroesophageal junction cancers have led to significant changes in the way these malignancies are managed. Although a relationship between gastroesophageal reflux disease and esophageal cancer has been demonstrated, antireflux surgery has been shown to have no preventive effect with regard to the development of esophageal adenocarcinoma. The newly modified staging system of the World Esophageal Cancer Consortium has helped define the optimal number of lymph nodes to dissect during an esophagectomy. Incorporating modern techniques, such as esophageal ultrasound, fine needle aspiration, and positron emission tomography, can improve the prognostic value of staging. Use of higher-volume centers and higher-volume surgeons for the performance of procedures in upper gastrointestinal cancers is associated with better outcomes. Neoadjuvant chemoradiation using a wide variety of chemotherapy regimens appears to have become the new standard of care for stage II and III esophageal cancer.